High school athlete back on the football field months after going into cardiac arrest

Nate Bentley went into cardiac arrest during a track meet. He was diagnosed with a rare, genetic heart rhythm disorder.
Healio

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a rare genetic ventricular tachycardia which can result in sudden cardiac death and/or syncope in young individuals with structurally ...
Yahoo Finance

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

CHARLESTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a clinical stage life sciences company developing precision genetic medicines for neuromuscular and cardiac ...
manilatimes

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Gabriel Brooks, M.D., Chief Medical Officer of Solid, said: "Despite being identified nearly 50 years ago, CPVT still lacks FDA-approved therapies - this announcement reflects a critical development ...
Business Wire

ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia

ARDSLEY, N.Y.--(BUSINESS WIRE)--ARMGO Pharma, Inc. (ARMGO), a clinical stage biopharmaceutical company advancing a novel class of small molecule drugs known as Rycals®, announced today the enrollment ...

Solid Biosciences to Present at Upcoming Scientific Meetings

Following completion of the conference, presentations will be available on the Scientific Publications & Presentations page of the Our Science section of the Company website, or by clicking here.
Mena FN

Solid Biosciences Receives FDA Fast Track Designation For SGT-501 First-In-Class Gene Therapy For Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

- Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to address underlying causes of CPVT, a life-threatening, arrhythmogenic cardiac condition - - Solid ...
Yahoo Finance

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

CHARLESTOWN, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular ...
Mena FN

Solid Biosciences Announces FDA IND And Health Canada CTA Approval For First-In-Class Cardiac Gene Therapy To Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

(MENAFN- GlobeNewsWire - Nasdaq) - SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies - - SGT-501 has received Orphan Drug ...